PT - JOURNAL ARTICLE AU - Davis, Christopher N. AU - Rock, Kat S. AU - Antillón, Marina AU - Miaka, Erick Mwamba AU - Keeling, Matt J. TI - Cost-effectiveness modelling to optimise active screening strategy for <em>gambiense</em> human African trypanosomiasis in the Democratic Republic of Congo AID - 10.1101/2020.08.03.20167296 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.03.20167296 4099 - http://medrxiv.org/content/early/2020/08/04/2020.08.03.20167296.short 4100 - http://medrxiv.org/content/early/2020/08/04/2020.08.03.20167296.full AB - Gambiense human African trypanosomiasis (gHAT) has been brought under control recently with village-based active screening playing a major role in case reduction. In the eve of elimination, we investigate how to optimise active screening in villages in the Democratic Republic of Congo, such that the expenses of screening programmes can be efficiently allocated while continuing to avert morbidity and mortality. We implement a cost-effectiveness analysis using a stochastic gHAT infection model for a range of active screening strategies and we calculate the net monetary benefit (NMB) of each strategy. High-coverage active screening strategies, occurring approximately annually, attain the highest NMB. We find that, for strategies stopping after one to three years of zero case reporting, the expected cost-benefits are very similar and we highlight the current recommended strategy (three years before stopping) is likely cost-effective, in addition to providing valuable information on whether transmission has been interrupted.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Bill and Melinda Gates Foundation (www.gatesfoundation.org) in partnership with the Task Force for Global Health through the NTD Modelling Consortium [OPP1184344] (C.N.D., K.S.R. and M.J.K.), the Bill and Melinda Gates Foundation through the Human African Trypanosomiasis Modelling and Economic Predictions for Policy (HAT MEPP) project [OPP1177824] (K.S.R., M.A., and M.J.K.), and EPSRC/MRC via the MathSys Centre for Doctoral Training (C.N.D. and M.J.K.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors thank PNLTHA for original data collection and WHO for data access in the framework of the WHO HAT Atlas (Franco et al, 2020)(https://doi.org/10.1371/journal.pntd.0008261).